• SPX
  • $5,832.92
  • 0.16 %
  • $9.40
  • DJI
  • $42,233.05
  • -0.36 %
  • -$154.52
  • N225
  • $39,277.39
  • 0.96 %
  • $373.71
  • FTSE
  • $8,219.61
  • -0.8 %
  • -$66.01
  • IXIC
  • $18,712.75
  • 0.78 %
  • $145.56
Amneal Pharmaceuticals, Inc. (AMRX) Stock Price, News & Analysis

Amneal Pharmaceuticals, Inc. (AMRX) Stock Price, News & Analysis

Currency in USD Disclaimer

$8.56

$0.02

(0.18%)

Day's range
$8.47
Day's range
$8.59
50-day range
$8.01
Day's range
$8.95
  • Country: US
  • ISIN: US03168L1052
52 wk range
$3.72
Day's range
$8.95


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.18
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (AMRX)
  • Company Amneal Pharmaceuticals, Inc.
  • Price $8.56
  • Changes Percentage (0.18%)
  • Change $0.02
  • Day Low $8.47
  • Day High $8.59
  • Year High $8.95

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/07/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $8.00
  • High Stock Price Target $12.00
  • Low Stock Price Target $4.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.73
  • Trailing P/E Ratio -9.25
  • Forward P/E Ratio -9.25
  • P/E Growth -9.25
  • Net Income $-83,993,000

Income Statement

Quarterly

Annual

Latest News of AMRX

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.